Today, Dassault Systèmes announced a strategic investment in Click Therapeutics, having provided the entire Series C funding round, which closed earlier in March. The investment establishes a strong and future-forward partnership between Click Therapeutics and Dassault Systèmes’ Medidata Solutions designed to extend the patient experience beyond clinical trials to include digital therapeutics in the real world, enabling both enhanced long-term patient benefit and robust real-world data opportunities.

The expanded relationship between Click and Medidata will set a gold standard and unified offering for digital plus drug clinical trial design and execution, and provide a clear path to best-in-class Prescription Digital Therapeutics and Software-Enhanced Drugs™ product approvals for therapeutic innovators worldwide. Building upon Medidata’s existing customer base of over 2,300 life sciences clients, this partnership will both extend the reach of Click’s capabilities as well as the benefits of digital therapies to more patients.

Read the full press release here.